Drugs / CV8102
CV8102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03291002 | Sep 2017 → Oct 2022 | adenoid cystic carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma, skin squamous cell carcinoma | CureVac | Unknown | No outcome recorded |
| Phase 1 | NCT02238756 | Sep 2014 → Sep 2015 | rabies | CureVac | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03203005 | Sep 2017 → Dec 2019 | hepatocellular carcinoma | National Cancer Institute, Naples | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV8102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03291002 ↗ |
| Known as | Rna-based adjuvant cv8102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802202 ↗ |
| Known as | RNAdjuvant | “CV8102 adjuvant (RNAdjuvant®) following a single pre-vaccination infusion” NCT03203005 ↗ |
| Action | Activate | “TLR7/8/RIG I agonist CV8102” PMID 35421231 ↗ Jun 2022 |
| Modality | Other / unclassified | “CV8102 is an RNA-based immunostimulator inducing a balanced Th1/Th2 immune response.” PMID 35421231 ↗ Jun 2022 |
| Route | Intramuscular | “2 intramuscular doses of CV8102” NCT02238756 ↗ |